Prostaglandin F2alpha Antikörper (Cy7)
Kurzübersicht für Prostaglandin F2alpha Antikörper (Cy7) (ABIN2178428)
Target
Alle Prostaglandin F2alpha Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Kreuzreaktivität
- Ratte
-
Kreuzreaktivität (Details)
- PGF2 Alpha
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated to PGF2 Alpha
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- IF(IHC-P) 1:50-200
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- Prostaglandin F2alpha
-
Andere Bezeichnung
- Pgf2 alpha
-
Hintergrund
-
Synonyms: Prostaglandin F2 Alpha, PGF2 Alpha, 5Z,9,11,13E,15S-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt, PGF2−,Tris.
Background: Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds. A positive feedback loop between endometrial PG F2 and luteal oxytocin is responsible for completion of luteolysis.Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds. Also stimulates contraction of smooth muscle, such as in bronchi, with possible involvement in asthma. This effect is at least partially mediated through tachykinin release.
Target
-